论文部分内容阅读
目的:研究胃癌患者术后应用细胞因子诱导的杀伤细胞(CIK)免疫联合化疗的临床效果。方法:选取2005年6月~2010年6月之间于我院接受手术治疗的胃癌患者200例,将其随机均分为两组。术后对照组单纯实施化疗,观察组实施CIK免疫联合化疗治疗,对其进行至少5年的随访,统计生存率、无进展生存率与生产期。结果:观察组的3年、5年生存率分别为62.0%和56.0%,均高于对照组(46.0%和25.0%),生存期平均(58.8±2.3)个月,长于对照组的(26.4±2.1)个月,P<0.05;观察组的3年、5年无进展生存率分别为49.0%和48.0%,高于对照组(30.0%和20.0%),无进展生存期平均(34.8±1.6)个月,长于对照组的(20.8±1.8)个月,P<0.05,差异均具有统计学意义。结论:相比于单纯化疗,对胃癌术后患者实施CIK免疫联合化疗可以抑制癌症进展或复发,延长患者生存期,使其生存率与无进展生存率提高,疗效显著,值得推广。
Objective: To study the clinical effect of cytokine-induced killer (CIK) immunotherapy combined with chemotherapy in patients with gastric cancer. Methods: 200 patients with gastric cancer undergoing surgery in our hospital from June 2005 to June 2010 were randomly divided into two groups. The patients in the control group were treated with chemotherapy alone and the observation group were treated with CIK combined with chemotherapy. The patients were followed up for at least 5 years. The statistical survival rate, progression-free survival rate and the production period were observed. Results: The 3-year and 5-year survival rates of the observation group were 62.0% and 56.0%, respectively, which were significantly higher than those of the control group (46.0% and 25.0%, 58.8 ± 2.3) ± 2.1) months, P <0.05. The three-year and five-year progression-free survival rates in the observation group were 49.0% and 48.0% respectively, which were significantly higher than those in the control group (30.0% and 20.0% 1.6) months, longer than the control group (20.8 ± 1.8) months, P <0.05, the differences were statistically significant. Conclusion: Compared with chemotherapy alone, CIK immunotherapy combined with chemotherapy for postoperative patients with gastric cancer can inhibit the progression or recurrence of cancer, prolong the survival of patients and improve the survival rate and progression-free survival rate, which is worthy of promotion.